Nkarta (NKTX) to Release Earnings on Tuesday

Nkarta (NASDAQ:NKTX) is expected to be posting its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($0.32) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, April 3, 2026 at 4:00 PM ET.

Nkarta Stock Up 1.9%

Nkarta stock opened at $2.18 on Tuesday. The stock has a market cap of $154.85 million, a P/E ratio of -1.58 and a beta of 0.47. The company’s 50 day moving average price is $2.28 and its two-hundred day moving average price is $2.10. Nkarta has a 52 week low of $1.31 and a 52 week high of $2.81.

Insider Activity

In other Nkarta news, CEO Paul J. Hastings sold 26,046 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $2.07, for a total value of $53,915.22. Following the sale, the chief executive officer directly owned 390,023 shares in the company, valued at $807,347.61. The trade was a 6.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 8.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Nkarta

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Abel Hall LLC purchased a new stake in Nkarta during the fourth quarter valued at about $27,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Nkarta in the fourth quarter worth about $37,000. Prelude Capital Management LLC bought a new stake in shares of Nkarta in the third quarter valued at approximately $90,000. Man Group plc purchased a new stake in shares of Nkarta during the 3rd quarter valued at approximately $90,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Nkarta by 45.8% during the 4th quarter. Wells Fargo & Company MN now owns 47,997 shares of the company’s stock valued at $89,000 after buying an additional 15,079 shares in the last quarter. 80.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on NKTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Nkarta in a research report on Monday, December 29th. Wall Street Zen upgraded Nkarta from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $13.25.

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.